Emerging antibody-based HER2 (ErbB-2/neu) therapeutics.

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• HER2 receptor tyrosine kinase is a key target in breast and epithelial cancers.
• Antibody-based therapeutics targeting HER2 include monoclonal antibodies, immunotoxins, and bispecific antibodies.
• Selective delivery of anticancer agents to HER2-overexpressing tumor cells can reduce host toxicity.

Purpose of the Study:

• To review advances in antibody-based HER2-targeting strategies.
• To focus on preclinical development of anti-HER2 immunoliposomes (ILs) for targeted drug delivery.
• To evaluate the therapeutic efficacy of anti-HER2 ILs-doxorubicin (dox).

Main Methods:

• Review of recent advances in antibody-based HER2-targeting strategies.
• Preclinical development and testing of anti-HER2 immunoliposomes (ILs).
• In vitro and in vivo efficacy and tumor uptake studies in human tumor xenograft models.

Main Results:

• Anti-HER2 ILs-doxorubicin demonstrated superior therapeutic efficacy compared to free doxorubicin or liposomal doxorubicin.
• Anti-HER2 ILs-doxorubicin showed greater efficacy than combinations of doxorubicin, liposomal doxorubicin, and rhuMAbHER2.
• Extensive preclinical data support the effectiveness of anti-HER2 ILs-doxorubicin.

Conclusions:

• Anti-HER2 immunoliposomes represent a promising platform technology for targeted anticancer drug delivery.
• Anti-HER2 ILs-doxorubicin are approaching clinical testing for advanced HER2-overexpressing breast cancer.
• Future applications include intracellular delivery of other anticancer agents and therapeutic nucleic acids.